BAF · CBAF312A2304
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of siponimod (BAF312) in patients with secondary progressive multiple sclerosis, followed by an open-label BAF312 extension.
Sponsor: NOVARTIS
Phase: III
Area: Neuroimmunology